- Medibank Private reported a net income of A$343.2 million in the first half of the year.
- The company has declared an interim dividend per share of A$0.0720.
- Net investment income for the period stands at A$83.6 million.
- There have been 7 buys and 5 holds of the company’s shares, with no sells reported.
A look at Medibank Private Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medibank Private Limited, a private health care provider in Australia, has received promising scores on Smartkarma’s Smart Scores. The company’s overall outlook is looking positive, with a score of 4 out of 5 for both growth and resilience, and a score of 3 for dividends. These scores indicate that Medibank Private is projected to experience steady growth, and has a strong ability to withstand market fluctuations. This is good news for customers who rely on Medibank for their health insurance needs.
With a score of 2 for value, Medibank Private may not be the most affordable option for health insurance, but its strong scores in other areas make it a reliable choice for customers. The company offers a range of health insurance products, including coverage for hospital and ancillary services, as well as travel, pet, and life insurance for overseas students and visitors. This diverse range of offerings makes Medibank Private a trusted and comprehensive provider of health care coverage in Australia.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
